- Home
- TLPH vs ADVB Comparison
TLPH vs ADVB Comparison
Compare TLPH & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- ADVB
- Stock Information
- Founded
- TLPH 2005
- ADVB 2014
- Country
- TLPH United States
- ADVB United States
- Employees
- TLPH N/A
- ADVB N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- TLPH Health Care
- ADVB Health Care
- Exchange
- TLPH Nasdaq
- ADVB Nasdaq
- Market Cap
- TLPH 11.1M
- ADVB 9.1M
- IPO Year
- TLPH 2011
- ADVB 2025
- Fundamental
- Price
- TLPH $0.94
- ADVB $0.56
- Analyst Decision
- TLPH Strong Buy
- ADVB
- Analyst Count
- TLPH 1
- ADVB 0
- Target Price
- TLPH $6.00
- ADVB N/A
- AVG Volume (30 Days)
- TLPH 4.3M
- ADVB 373.8K
- Earning Date
- TLPH 11-12-2025
- ADVB 11-03-2025
- Dividend Yield
- TLPH N/A
- ADVB N/A
- EPS Growth
- TLPH N/A
- ADVB N/A
- EPS
- TLPH N/A
- ADVB N/A
- Revenue
- TLPH $27,000.00
- ADVB N/A
- Revenue This Year
- TLPH N/A
- ADVB N/A
- Revenue Next Year
- TLPH $14,533.26
- ADVB N/A
- P/E Ratio
- TLPH N/A
- ADVB N/A
- Revenue Growth
- TLPH N/A
- ADVB N/A
- 52 Week Low
- TLPH $0.38
- ADVB $0.34
- 52 Week High
- TLPH $1.20
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- TLPH 75.75
- ADVB N/A
- Support Level
- TLPH $0.88
- ADVB N/A
- Resistance Level
- TLPH $1.20
- ADVB N/A
- Average True Range (ATR)
- TLPH 0.13
- ADVB 0.00
- MACD
- TLPH 0.03
- ADVB 0.00
- Stochastic Oscillator
- TLPH 62.70
- ADVB 0.00
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.